CLDN18 and neoplasm: We also report the concordance of CLDN18.2 positivity in a subset of pair-matched samples consisting of archival tumor samples and baseline tumor samples from the phase 2 ILUSTRO study (NCT03505320; cohorts 1A and 2) and a phase 1 study in Japanese patients (NCT03528629) [28, 29].